Roche has signed a strategic collaboration with GE Healthcare to co-develop and co-market digital clinical decision support solutions to improve treatment for oncology and critical care patients.
The long-term partnership will use advanced analytics to develop a digital platform for providing workflow solutions and applications that support clinical decisions.
Through the new platform, the firms intend to enable optimised integration and analysis of in-vivo and in-vitro data, medical best practice, patient records, real-time monitoring, and latest research outcomes.
These insights will provide clinicians with comprehensive decision support to deliver the right treatment and quality of care.
Roche Diagnostics CEO Roland Diggelmann said: “This unique partnership will deliver innovative solutions and insights in clinical decision-making.
“Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings.”
The platform will provide a comprehensive data dashboard that can be used by multiple specialists in an oncology care team for review, collaboration and alignment of treatment decisions for patients at each stage of their disease.
In a critical care setting, the digital platform could be used to integrate data from a patient’s hospital monitoring equipment with their biomarker, genomic and sequencing data.
This integration is expected to aid in the identification or prediction of severe complications prior to occurrence.
GE Healthcare president and CEO Kieran Murphy said: “This is the first time that two major players in healthcare have combined digital, in-vivo and in-vitro diagnostics to this degree.
“We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”